#1
#1 out of 1562.0 est. views
business20h ago
JPM26 Day 2: Companies Lay Out Near-Term Revenue, Longer-Term Business Goals
- AstraZeneca reiterates an $80B revenue goal for 2030 and outlines near-term launches to support it.
- BioNTech shifts focus from COVID to cancer, prioritizing late-stage readouts and pumitamig programs.
- AbbVie acquires ex-China rights to a PD-1/VEGF bispecific from RemeGen, signaling aggressive positioning in bispecifics.
- Agios projects a $10B market by 2030, expanding beyond ultra-rare diseases into broader portfolios.
- Acadia aims for $1B Nuplazid and $700M Daybue sales by 2028, signaling aggressive growth expectations.
- Policy moves at JPM26 show Acadia CEO lobbying against MFN pricing for small biotechs.
- Company reports highlight a broader trend of near-term launches underpinning long-term revenue plans.
- BioNTech’s pumitamig could become a next-generation IO backbone if readouts are favorable.
- BMO analysts see eight pivotal studies across oncology signaling significant execution risk and potential upside for BioNTech.
- The JPM26 event underscored how near-term product launches align with longer-term pipeline value.
Vote 0